ClinicalTrials.gg
CompletedNCT03609593Updated Oct 7, 2026Results posted

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

A Phase 2 interventional study of Bendamustine and Venetoclax in Chronic Lymphocytic Leukemia, sponsored by Nicole Lamanna. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Nicole Lamanna · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 3 under way, 1 of them phase 3. bendamustine · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
20th of 46
42 · median 35
Started
2018
with 1 other
Phase 2
22 of 46
1 open now
Registered
43rd of 46
by date

Among the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 20th largest by enrollment, is one of 2 that started in 2018, is one of 22 in phase 2, and was the 43rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of bendamustine and rituximab (BR) followed by venetoclax for 12 months. The total time on therapy is 15 months. Bendamustine and rituximab is a commonly used treatment for CLL. Venetoclax is an oral drug that blocks a protein called BCL-2 which is present on CLL cells. It is approved for patients with relapsed (the cancer has come back) or refractory (the cancer did not respond) CLL who harbor a deletion in the short arm of chromosome 17 [del(17p)]. When this drug is used by itself, many patients needed to be admitted to the hospital to monitor for a complication known as tumor lysis syndrome. This is an oncologic emergency that is caused by massive destruction of tumor cells with the release of large amounts of electrolytes and other molecules into the blood that can lead to renal failure and potentially death.

Read the detailed description

This is a single arm multicenter phase II study using bendamustine-rituximab (BR) followed by venetoclax and rituximab for the upfront treatment of chronic lymphocytic leukemia (CLL). The activity, safety, and survival data have been presented previously for BR alone in patients with previously untreated disease and venetoclax alone in relapsed/refractory patients and those with high-risk disease. After pretreatment evaluation, patients will receive three cycles of BR followed by venetoclax via a five-week dose escalation to 400 mg daily. Once patients reach 400 mg of venetoclax daily, patients will receive six cycles (months) of rituximab as consolidation. Total time of venetoclax therapy will be 12 cycles and total time on therapy (BR plus venetoclax plus rituximab) will be 15 cycles. Responses and endpoints will be assessed after 3, 6, 9 (laboratory only), 12, 18, 24, 30, and 36 cycles. Minimal residual disease (MRD) testing will be done after 3, 6, 9, 12, 18, and 24 cycles via an 8-color flow cytometry panel. Bone marrow testing for MRD can be performed if the peripheral blood is MRD negative (or was MRD negative at the last test). Anti-infective prophylaxis against H. zoster and P. jiroveci will be mandated. Tumor lysis syndrome (TLS) prophylaxis with allopurinol and/or an alternative will be mandated.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Leukemia
  • Bendamustine
  • Rituximab
  • Venetoclax
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age.
  • Diagnosed with CLL
  • To be considered CLL, the subject must have an absolute lymphocytosis in the blood of at least 5,000 lymphocytes per microliter, or bone marrow lymphocytosis greater than or equal to 30% of all nucleated cells.
  • Histologic and immunophenotypic analysis should demonstrate small to moderate size lymphocytes with flow cytometry demonstrating a certain population of lymphocytes.
  • No prior therapy for their disease. Topical or inhaled are permitted for other medical conditions, ie asthma or dermatologic reasons.
  • Eastern Oncology Cooperative Group () performance score of ≤ 2.
  • Subjects with hemolytic anemia or autoimmune thrombocytopenia will be eligible for treatment on this protocol regardless of disease stage upon discussion with the principal investigator.
  • An > 1.0 109/L; > 8 g/dL; or a count > 50 x 109/L (unless due to bone marrow failure).
  • Adequate hepatic function
  • (aPTT) and prothrombin time (PT) not to exceed 1.5x the upper limit of reference ranges.
  • Ability to understand and the willingness to sign a written document.
  • Women of and men must agree to use adequate (see below) for at least 90 days prior to study entry and for the duration of study participation.

    • For women of childbearing potential (WCBP): a negative serum β-human chorionic gonadotropin (βhCG) pregnancy test must be performed within 1 week before randomization (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally for at least 24 consecutive months [women ≤ 55 years] or 12 consecutive months [women > 55 years]).
    • Male and female subjects who are not surgically sterile or postmenopausal must be willing to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of study drug. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have been previously treated for CLL or small lymphocytic lymphoma (SLL), except with for symptom relief.
  • Treatment with any of the following within 7 days prior to the first dose of study drug:

    • Steroid therapy for anti-neoplastic intent
    • moderate or strong cytochrome P450 3A () inhibitors
    • moderate or strong CYP3A inducers
  • Subject has known allergy to both xanthine oxidase inhibitors and/or rasburicase.
  • Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
  • Subject has evidence of other uncontrolled condition(s) including, but not limited to:

    1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
    2. Chronic virus (HBV) or (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
  • Subject is known to be positive for . (HIV testing is not required.)
  • (NYHA) class II-IV heart failure or arrhythmia requiring treatment.
  • Pregnant or lactating women. Women and men of childbearing age should use effective .
  • Subject has a history of active other than CLL within the past 2 years prior to study entry with the exception of: adequately treated in situ carcinoma of the cervix uteri, adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin, or previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • Subjects may receive intravenous immunoglobulin (IVIG) for hypogammaglobulinemia while on protocol. Subjects may receive erythropoietin, filgrastim, pegfilgrastim, or sargramostim while on protocol.
  • Subject has malabsorption syndrome or other condition that precludes enteral route of administration.
  • Subjects with known Richter's syndrome or a history of Richter's syndrome.
  • Subjects who are are actively being treated for a non-hematologic disease, or are on other immunomodulatory agents (e.g. cyclosporine, tacrolimus, etc.) will be excluded.
  • Subjects who have received an stem cell transplant.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCL-2 inhibitors, bendamustine, or anti-CD20 monoclonal antibodies.
  • Administration or consumption of any of the following within 3 days prior to the first dose of study drug:

    • Grapefruit or grapefruit products
    • Seville oranges (including marmalade containing Seville oranges)
    • Star fruit
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    BR followed by venetoclax and rituximab

    Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.

    Drug: Bendamustine · Drug: Venetoclax · Drug: Rituximab

Interventions

  • Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.

    Also known as: Treanda

  • Venetoclax: 12 cycles Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows: * Cycle 4 days 1-7 (Week 1): 20 mg once daily * Cycle 4 days 8-14 (Week 2): 50 mg once daily * Cycle 4 days 15-21 (Week 3): 100 mg once daily * Cycle 4 days 22-28 (Week 4): 200 mg once daily * Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration.

    Also known as: ABT-199, Venclexta

  • For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) After the Completion of All Therapy

    Number of patients with reduction in tumor burden of a predefined amount

    Time frame: 15 months

07

Results

Posted Oct 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneBR-VR
Started42
Completed39
Not completed3

Outcome measures

PrimaryOverall Response Rate (ORR) After the Completion of All Therapy

Number of patients with reduction in tumor burden of a predefined amount

Time frame:
15 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) After the Completion of All Therapy
ParticipantsBR-VR
Overall Response Rate (ORR) After the Completion of All Therapy36

Adverse events

Collected over Up to approximately 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BR-VR3/42 (7.1%)15/42 (35.7%)42/42 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventBR-VR
FeverGeneral disorders and administration site conditions7/42
Febrile neutropeniaBlood and lymphatic system disorders3/42
COVID-19 infectionRespiratory, thoracic and mediastinal disorders2/42
Acute kidney injuryRenal and urinary disorders1/42
Altered Mental StatusPsychiatric disorders1/42
Atrial fibrillationCardiac disorders1/42
C-Difficile ColitisGastrointestinal disorders1/42
EncephalopathyNervous system disorders1/42
La Crosse VirusInfections and infestations1/42
Lung infectionInfections and infestations1/42
Most frequent other events
Showing 10 of 200
Most frequent other events
EventBR-VR
FatigueGeneral disorders and administration site conditions33/42
AnemiaBlood and lymphatic system disorders25/42
Neutrophil count decreasedInvestigations25/42
DiarrheaGastrointestinal disorders24/42
NauseaGastrointestinal disorders24/42
CoughRespiratory, thoracic and mediastinal disorders20/42
Platelet count decreasedInvestigations20/42
White blood cell decreasedInvestigations20/42
HeadacheNervous system disorders19/42
Creatinine increasedInvestigations16/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)BR-VR
Median61.5 (38 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)BR-VR
Female13
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BR-VR
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported24
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BR-VR
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White29
More than one race0
Unknown or Not Reported8
Region of Enrollment
Region of Enrollment(participants)BR-VR
United States42
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(Participants)BR-VR
ECOG score = 021
ECOG score = 119
ECOG score = 22
08

Study locations

1 site
  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jan 2026, 86 months.

Results were first posted in Oct 2026, 8 months after primary completion.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 86 months is above that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2018
First posted
Aug 1, 2018
StartActual
Nov 12, 2018
Primary completionActual
Jan 27, 2026
CompletionActual
Jan 27, 2026
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOverall response rateResponse Rate (ORR) afterAfter the completionCompletion of all therapyAll TherapyTime frame: 15 months
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall response rateResponse Rate (ORR) afterAfter the completionCompletion of all therapyAll TherapyTime frame: 15 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03609593
Lead sponsor
Nicole Lamanna
Responsible party
Nicole Lamanna (Associate Clinical Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Aug 1, 2018
Start date
Nov 12, 2018
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Nicole Lamanna, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Venetoclax · Rituximab

Start the discussion